Share
array:24 [
"pii" => "S217357432100215X"
"issn" => "21735743"
"doi" => "10.1016/j.reumae.2021.06.003"
"estado" => "S300"
"fechaPublicacion" => "2022-10-01"
"aid" => "1552"
"copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
"copyrightAnyo" => "2021"
"documento" => "simple-article"
"crossmark" => 1
"subdocumento" => "crp"
"cita" => "Reumatol Clin. 2022;18:475-9"
"abierto" => array:3 [
"ES" => false
"ES2" => false
"LATM" => false
]
"gratuito" => false
"lecturas" => array:1 [
"total" => 0
]
"Traduccion" => array:1 [
"es" => array:19 [
"pii" => "S1699258X21001571"
"issn" => "1699258X"
"doi" => "10.1016/j.reuma.2021.06.001"
"estado" => "S300"
"fechaPublicacion" => "2022-10-01"
"aid" => "1552"
"copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
"documento" => "simple-article"
"crossmark" => 1
"subdocumento" => "crp"
"cita" => "Reumatol Clin. 2022;18:475-9"
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"es" => array:12 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Original breve</span>"
"titulo" => "Niveles de fármacos anti-TNFα en pacientes con artritis reumatoide y espondiloartritis"
"tienePdf" => "es"
"tieneTextoCompleto" => "es"
"tieneResumen" => array:2 [
0 => "es"
1 => "en"
]
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "475"
"paginaFinal" => "479"
]
]
"titulosAlternativos" => array:1 [
"en" => array:1 [
"titulo" => "Anti-TNFα Drug Levels in Patients with Rheumatoid Arthritis and Spondyloarthritis"
]
]
"contieneResumen" => array:2 [
"es" => true
"en" => true
]
"contieneTextoCompleto" => array:1 [
"es" => true
]
"contienePdf" => array:1 [
"es" => true
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Erardo Meriño-Ibarra, Francisco Javier Manero Ruíz"
"autores" => array:2 [
0 => array:2 [
"nombre" => "Erardo"
"apellidos" => "Meriño-Ibarra"
]
1 => array:2 [
"nombre" => "Francisco Javier"
"apellidos" => "Manero Ruíz"
]
]
]
]
]
"idiomaDefecto" => "es"
"Traduccion" => array:1 [
"en" => array:9 [
"pii" => "S217357432100215X"
"doi" => "10.1016/j.reumae.2021.06.003"
"estado" => "S300"
"subdocumento" => ""
"abierto" => array:3 [
"ES" => false
"ES2" => false
"LATM" => false
]
"gratuito" => false
"lecturas" => array:1 [
"total" => 0
]
"idiomaDefecto" => "en"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432100215X?idApp=UINPBA00004M"
]
]
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X21001571?idApp=UINPBA00004M"
"url" => "/1699258X/0000001800000008/v1_202210010847/S1699258X21001571/v1_202210010847/es/main.assets"
]
]
"itemSiguiente" => array:19 [
"pii" => "S2173574321001684"
"issn" => "21735743"
"doi" => "10.1016/j.reumae.2021.04.004"
"estado" => "S300"
"fechaPublicacion" => "2022-10-01"
"aid" => "1554"
"copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "fla"
"cita" => "Reumatol Clin. 2022;18:480-5"
"abierto" => array:3 [
"ES" => false
"ES2" => false
"LATM" => false
]
"gratuito" => false
"lecturas" => array:1 [
"total" => 0
]
"en" => array:12 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
"titulo" => "Usefulness of rheumatology consultancy in situ: Analysis of a long-term experience"
"tienePdf" => "en"
"tieneTextoCompleto" => "en"
"tieneResumen" => array:2 [
0 => "en"
1 => "es"
]
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "480"
"paginaFinal" => "485"
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Utilidad de la consultoría reumatológica <span class="elsevierStyleItalic">in situ</span>: análisis de una experiencia prolongada en el tiempo"
]
]
"contieneResumen" => array:2 [
"en" => true
"es" => true
]
"contieneTextoCompleto" => array:1 [
"en" => true
]
"contienePdf" => array:1 [
"en" => true
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Jesús Tornero-Molina, María Luisa Díez-Andrés, Fernando Alonso, Cintia de la Llana-Calvo, Susana Luengo Rojo, Elena Casado Silvestre, Raquel Grado Sanz"
"autores" => array:7 [
0 => array:2 [
"nombre" => "Jesús"
"apellidos" => "Tornero-Molina"
]
1 => array:2 [
"nombre" => "María Luisa"
"apellidos" => "Díez-Andrés"
]
2 => array:2 [
"nombre" => "Fernando"
"apellidos" => "Alonso"
]
3 => array:2 [
"nombre" => "Cintia"
"apellidos" => "de la Llana-Calvo"
]
4 => array:2 [
"nombre" => "Susana"
"apellidos" => "Luengo Rojo"
]
5 => array:2 [
"nombre" => "Elena"
"apellidos" => "Casado Silvestre"
]
6 => array:2 [
"nombre" => "Raquel"
"apellidos" => "Grado Sanz"
]
]
]
]
]
"idiomaDefecto" => "en"
"Traduccion" => array:1 [
"es" => array:9 [
"pii" => "S1699258X21001595"
"doi" => "10.1016/j.reuma.2021.04.015"
"estado" => "S300"
"subdocumento" => ""
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"idiomaDefecto" => "es"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X21001595?idApp=UINPBA00004M"
]
]
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321001684?idApp=UINPBA00004M"
"url" => "/21735743/0000001800000008/v1_202210070758/S2173574321001684/v1_202210070758/en/main.assets"
]
"itemAnterior" => array:18 [
"pii" => "S2173574322001393"
"issn" => "21735743"
"doi" => "10.1016/j.reumae.2022.08.002"
"estado" => "S300"
"fechaPublicacion" => "2022-10-01"
"aid" => "1551"
"copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "fla"
"cita" => "Reumatol Clin. 2022;18:469-74"
"abierto" => array:3 [
"ES" => false
"ES2" => false
"LATM" => false
]
"gratuito" => false
"lecturas" => array:1 [
"total" => 0
]
"en" => array:13 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
"titulo" => "Anti-Carbamylated Protein Antibodies, Tumour Necrosis Factor Alpha and Insulin Resistance in Egyptian Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus"
"tienePdf" => "en"
"tieneTextoCompleto" => "en"
"tieneResumen" => array:2 [
0 => "en"
1 => "es"
]
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "469"
"paginaFinal" => "474"
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Anticuerpos anti-proteína carbamilada, factor de necrosis tumoral alfa y resistencia a la insulina en pacientes egipcios con artritis reumatoide y lupus eritematoso sistémico"
]
]
"contieneResumen" => array:2 [
"en" => true
"es" => true
]
"contieneTextoCompleto" => array:1 [
"en" => true
]
"contienePdf" => array:1 [
"en" => true
]
"resumenGrafico" => array:2 [
"original" => 0
"multimedia" => array:7 [
"identificador" => "fig0010"
"etiqueta" => "Fig. 2"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr2.jpeg"
"Alto" => 1270
"Ancho" => 1675
"Tamanyo" => 60313
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Correlation between anti-carP antibody and DAS 28-ESR.</p>"
]
]
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Mohamed Sherif El Hawary, Sarah A. Hassan, Sahar Abd ELatty, Noha M. Khalil"
"autores" => array:4 [
0 => array:2 [
"nombre" => "Mohamed Sherif"
"apellidos" => "El Hawary"
]
1 => array:2 [
"nombre" => "Sarah A."
"apellidos" => "Hassan"
]
2 => array:2 [
"nombre" => "Sahar Abd"
"apellidos" => "ELatty"
]
3 => array:2 [
"nombre" => "Noha M."
"apellidos" => "Khalil"
]
]
]
]
]
"idiomaDefecto" => "en"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574322001393?idApp=UINPBA00004M"
"url" => "/21735743/0000001800000008/v1_202210070758/S2173574322001393/v1_202210070758/en/main.assets"
]
"en" => array:19 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Brief Report</span>"
"titulo" => "Anti-TNFα drug levels in patients with rheumatoid arthritis and spondyloarthritis"
"tieneTextoCompleto" => true
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "475"
"paginaFinal" => "479"
]
]
"autores" => array:1 [
0 => array:4 [
"autoresLista" => "Erardo Meriño-Ibarra, Francisco Javier Manero Ruíz"
"autores" => array:2 [
0 => array:4 [
"nombre" => "Erardo"
"apellidos" => "Meriño-Ibarra"
"email" => array:1 [
0 => "eemerinnoi@salud.aragon.es"
]
"referencia" => array:1 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">*</span>"
"identificador" => "cor0005"
]
]
]
1 => array:2 [
"nombre" => "Francisco Javier"
"apellidos" => "Manero Ruíz"
]
]
"afiliaciones" => array:1 [
0 => array:2 [
"entidad" => "Servicio de Reumatología, Hospital Universitario Miguel Servet, Zaragoza, Spain"
"identificador" => "aff0005"
]
]
"correspondencia" => array:1 [
0 => array:3 [
"identificador" => "cor0005"
"etiqueta" => "⁎"
"correspondencia" => "Corresponding author."
]
]
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Niveles de fármacos anti-TNFα en pacientes con artritis reumatoide y espondiloartritis"
]
]
"textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">In patients with rheumatoid arthritis (RA) treated with anti-TNF drugs (anti-TNF). A correlation has been found between drug levels and clinical response<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>. For example, in infliximab-treated patients, the presence of anti-drug antibodies (ADA) provoke loss of response, ifuional reactions and increased treatment withdrawal<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>. These data are not exclusive to RA and have also been described in spondyloarhritis (SpA), where anti-infliximab and anti-adalimumab antibodies are found in non-responders and in the case of infliximab, they are also related to infusional reactions, motivating a switch to another drug<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Various drug level measurement techniques are available with different standardisation<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>, creating uncertainty as to the value of measuring drug levels. A consensus article has recently been published with the aim of reducing this uncertainty in the Spanish setting<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The aims of this study were to compare anti-TNF levels in RA patients vs. SpA, in patients in remission/low disease activity (LDA) vs. non-remission/non-LDA according to rheumatic disease, and to determine the influence of the use of conventional synthetic disease-modifying drugs (DMARDs) on these levels.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Material and methods</span><p id="par0020" class="elsevierStylePara elsevierViewall">A total of 474 patients were being treated with anti-TNF drugs at our centre, including 51 patients with infliximab, 198 patients with adlmumab, and 225 patients with etanercept. A retrospective, observational study was conducted to measure anti-TNF levels and the presence of ADA in a group of consecutively selected patients who attended consultations at the rheumatology department of the Miguel Servet University Hospital.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Inclusion criteria</span><p id="par0025" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">•</span><p id="par0030" class="elsevierStylePara elsevierViewall">Adult patients on anti-TNF treatment.</p></li></ul></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Exclusion criteria</span><p id="par0035" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">•</span><p id="par0040" class="elsevierStylePara elsevierViewall">Patients who declined to participate in the study</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">•</span><p id="par0045" class="elsevierStylePara elsevierViewall">Patients under follow-up in other hospitals</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">•</span><p id="par0050" class="elsevierStylePara elsevierViewall">Diagnoses other than RA or SpA</p></li></ul></p><p id="par0055" class="elsevierStylePara elsevierViewall">The most commonly used methods for measuring levels are the sandwich ELISA and the indirect ELISA<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>. In our study, the sample was obtained on the day the drug was due to be administered (trough level), using the Promonitor® test from Laboratorios Grifols (sandwich ELISA), and according to the methodology described by Chen DY et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>. In cases with undetectable anti-TNF levels, Acaf was measured using the Promonitor® test from Laboratorios Grifols (bridge-type ELISA).</p><p id="par0060" class="elsevierStylePara elsevierViewall">The following data were collected from the patients’ clinical history:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">•</span><p id="par0065" class="elsevierStylePara elsevierViewall">Time of evolution of the disease</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">•</span><p id="par0070" class="elsevierStylePara elsevierViewall">Type and schedule of biologic treatment and DMARDs</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">•</span><p id="par0075" class="elsevierStylePara elsevierViewall">Adherence: percentage of the prescribed dosage of the drug that the patient withdraws from the hospital pharmacy.</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">•</span><p id="par0080" class="elsevierStylePara elsevierViewall">Disease activity: considering remission/low activity in patients with RA when they had a DAS28 (CRP) ≤ 3.2 and in patients with SpA a BASDAI ≤ 4 and ASDAS (CRP) ≤ 2.1. The activity indices were obtained from the consultation prior to the measurement of the levels.</p></li></ul></p><p id="par0085" class="elsevierStylePara elsevierViewall">With these data, a group of patients with RA and SpA was obtained and in each, subgroups with drug dosages according to the technical data sheet (standard dose) and others with dosages lower than those recommended (suboptimal dose), as well as patients with/without treatment with DMARDs.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Ethical aspects</span><p id="par0090" class="elsevierStylePara elsevierViewall">All patients signed an informed consent form for this study and for the use of biological samples for biomedical research. This study was approved by the Research Ethics Committee of the Autonomous Community of Aragon.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Statistical method</span><p id="par0095" class="elsevierStylePara elsevierViewall">Quantitative variables: distribution was determined with the Kolmogorov-Smirnov statistic (Lilliefors correction); in variables with N < 50, the Shapiro–Wilk statistic was applied; if the distribution was normal, the mean and standard deviation (SD) were determined; in variables with non-parametric distribution, the median and interquartile range (IQR) were determined. For differences between means and between medians: Student’s t test and Mann–Whitney U test were used, respectively. For qualitative variables: 2 × 2 contingency tables with Pearson’s Chi-square test. Statistical procedures were performed with the R statistical programme and calculated with a 95% confidence interval.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Results</span><p id="par0100" class="elsevierStylePara elsevierViewall">A total of 53, 73, and 78 patients on treatment with infliximab, adalimumab, and etanercept, respectively, were studied. In all cases, a single sample extraction was performed. Eleven patients were excluded due to AFA and absence of drug levels: 3 (5.6%) treated with infliximab, all with SpA, none treated with DMARDs; 8 (11%) treated with adalimumab, 2 with RA on leflunomide, 6 patients with SpA, one treated with leflunomide, the remaining 5 without DMARDs. No anti-etanercept antibodies were detected.</p><p id="par0105" class="elsevierStylePara elsevierViewall">No differences were found in drug levels according to disease type and disease activity. Patients with RA had a median DAS28: 2.79 (RI: 2.27−3.62) and those with SpA had a BASDAI of 3.47 (SD: 2.2) and an ASDAS of 1.70 (1.40−2.27). The variables studied are displayed in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">The percentage of remission/LDA in cases with RA and SpA was 74.3% and 77.8%, respectively. The time of disease progression was 12.9 years (RI: 7.49−22.5), with no differences between diseases (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>); adherence was ≥80% in 88.6% of cases.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Drug levels in patients on standard-dose anti-TNF were 2.2 g/mL (1.4–5.2), 4.9 g/mL (0.8−8.9), and 3.1 g/mL (2.3−4.4) for infliximab, adalimumab and etanercept, respectively (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>A), with no differences according to rheumatic disease (data not shown). We also found no differences in the group of cases with standard drug dosages, segmented by disease type and activity (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>B). When dividing patients with standard drug dosages according to treatment with/without DMARDs, we obtained significant differences in serum levels of infliximab and etanercept; adalimumab levels were similar in both groups (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>C), and subdividing these cases according to rheumatic disease, only etanercept levels exhibited differences in patients with SpA (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>C1).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Discussion</span><p id="par0120" class="elsevierStylePara elsevierViewall">The drug level achieved after the standard treatment regimen may differ from one patient to another; however, the drug level required to achieve remission may not differ, hence the importance of evidence to support monitoring of anti-TNF6 levels.</p><p id="par0125" class="elsevierStylePara elsevierViewall">The patients studied were fairly homogeneous, even between those in remission and non-remission; for instance, RA patients had generally low activity indices, which may have contributed to differences in drug levels not being conspicuous when comparing patient subgroups.</p><p id="par0130" class="elsevierStylePara elsevierViewall">With respect to infliximab, the study by Jurado T et al. found that most RA patients in remission at week 54 after perfusion displayed levels of 4.4 g/mL at week<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> whereas in our study at week 12, we logically found lower levels of infliximab, with no differences in the remission/LDA vs. non-remission/non-LDA groups. Our results show no difference between infliximab levels between RA and SpA; nevertheless, Padilla-Martínez EM et al. detected different infliximab trough levels between the 2 diseases<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a>, but did not exclude cases with ADA from the analysis; similarly, they had a smaller sample size.</p><p id="par0135" class="elsevierStylePara elsevierViewall">Sanmarti R et al. found adalimumab levels of 6.9 g/mL in patients with RA in remission<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a>. Pouw MF et al. suggest that they should have levels of between 5−8 g/mL<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a>, similar to what was found in our study in patients in remission. Finally, Kneepkens EL et al. obtained an etanercept level of 3.8 g/mL (2.5–5.2) in SpA patients with ASDAS < 2.1<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> and Sanmarti R et al. obtained etanercept levels of 2.3 g/mL in RA patients in remission<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a>. Our results were similar in both diseases excluding patients with suboptimal doses.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Anti-TNF levels can be affected by different factors such as comorbidity, route of drug administration, ADA formation, or the use of cSFs<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a>. In our study, we detected differences in drug levels between patients with/without cAMP for infliximab and etanercept; nonetheless, we found no differences for adalimumab levels. However, Vogelzang EH et al. found higher levels of adalimumab in patients with RA or psoriatic arthritis treated with methotrexate<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a>.</p><p id="par0145" class="elsevierStylePara elsevierViewall">In general, we did not find differences in drug levels according to disease activity, perhaps because of the homogeneity of the sample in this aspect, but if we add a cSF-MEF, then differences do emerge, mainly in SpA. Does this suggest the need to always use cSF-MEFs in association with anti-TNFs? Probably not routinely, albeit this opinion might be different if we assessed other biomarkers, such as the CXCL12 genotype or HLA-DQA1*05<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a>.</p><p id="par0150" class="elsevierStylePara elsevierViewall">One of the limitations of our study is that as it is observational, retrospective, and conducted in clinical practice. As such, we do not aways have the results for all the variables studied. In addition, when the sample was subdivided, it was reduced, in some cases losing representativeness of the population under study.</p><p id="par0155" class="elsevierStylePara elsevierViewall">In summary, we purport that anti-TNF drug levels will be modified by treatment with cAMP.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Funding</span><p id="par0160" class="elsevierStylePara elsevierViewall">This research has not received any specific public or private funding.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of interest</span><p id="par0165" class="elsevierStylePara elsevierViewall">None.</p></span></span>"
"textoCompletoSecciones" => array:1 [
"secciones" => array:11 [
0 => array:3 [
"identificador" => "xres1779554"
"titulo" => "Abstract"
"secciones" => array:5 [
0 => array:2 [
"identificador" => "abst0005"
"titulo" => "Background and objectives"
]
1 => array:2 [
"identificador" => "abst0010"
"titulo" => "Objectives"
]
2 => array:2 [
"identificador" => "abst0015"
"titulo" => "Materials and methods"
]
3 => array:2 [
"identificador" => "abst0020"
"titulo" => "Results"
]
4 => array:2 [
"identificador" => "abst0025"
"titulo" => "Conclusions"
]
]
]
1 => array:2 [
"identificador" => "xpalclavsec1562310"
"titulo" => "Keywords"
]
2 => array:3 [
"identificador" => "xres1779553"
"titulo" => "Resumen"
"secciones" => array:5 [
0 => array:2 [
"identificador" => "abst0030"
"titulo" => "Antecedentes y objetivos"
]
1 => array:2 [
"identificador" => "abst0035"
"titulo" => "Objetivos"
]
2 => array:2 [
"identificador" => "abst0040"
"titulo" => "Materiales y métodos"
]
3 => array:2 [
"identificador" => "abst0045"
"titulo" => "Resultados"
]
4 => array:2 [
"identificador" => "abst0050"
"titulo" => "Conclusiones"
]
]
]
3 => array:2 [
"identificador" => "xpalclavsec1562311"
"titulo" => "Palabras clave"
]
4 => array:2 [
"identificador" => "sec0005"
"titulo" => "Introduction"
]
5 => array:3 [
"identificador" => "sec0010"
"titulo" => "Material and methods"
"secciones" => array:4 [
0 => array:2 [
"identificador" => "sec0015"
"titulo" => "Inclusion criteria"
]
1 => array:2 [
"identificador" => "sec0020"
"titulo" => "Exclusion criteria"
]
2 => array:2 [
"identificador" => "sec0025"
"titulo" => "Ethical aspects"
]
3 => array:2 [
"identificador" => "sec0030"
"titulo" => "Statistical method"
]
]
]
6 => array:2 [
"identificador" => "sec0035"
"titulo" => "Results"
]
7 => array:2 [
"identificador" => "sec0040"
"titulo" => "Discussion"
]
8 => array:2 [
"identificador" => "sec0045"
"titulo" => "Funding"
]
9 => array:2 [
"identificador" => "sec0050"
"titulo" => "Conflict of interest"
]
10 => array:1 [
"titulo" => "References"
]
]
]
"pdfFichero" => "main.pdf"
"tienePdf" => true
"fechaRecibido" => "2020-09-07"
"fechaAceptado" => "2021-06-03"
"PalabrasClave" => array:2 [
"en" => array:1 [
0 => array:4 [
"clase" => "keyword"
"titulo" => "Keywords"
"identificador" => "xpalclavsec1562310"
"palabras" => array:3 [
0 => "Anti-TNFα levels"
1 => "Rheumatoid arthritis"
2 => "Spondyloarthritis"
]
]
]
"es" => array:1 [
0 => array:4 [
"clase" => "keyword"
"titulo" => "Palabras clave"
"identificador" => "xpalclavsec1562311"
"palabras" => array:3 [
0 => "Niveles de anti-TNFα"
1 => "Artritis reumatoide"
2 => "Espondiloartritis"
]
]
]
]
"tieneResumen" => true
"resumen" => array:2 [
"en" => array:3 [
"titulo" => "Abstract"
"resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background and objectives</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Knowledge of the levels of anti-TNFa drugs can modify treatment in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objectives</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">To compare the levels of anti-TNFa in patients with RA vs SpA, in different clinical situations.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Materials and methods</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">A retrospective, observational study was conducted. Levels of anti-TNFa and the presence of anti-drug antibodies were measured in consecutively selected patients, using the ELISA technique.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Fifty-three, 73 and 78 patients treated with infliximab, adalimumab and etanercept were studied, respectively. The median drug levels in patients using standard doses were infliximab 2.2 µg/mL (1.4–5.2), adalimumab 4.9 µg/mL (0.8−8.9) and etanercept 3.1 µg/mL (2.3−4.4). There were no differences in drug levels according to disease activity but we found differences in etanercept and infliximab levels according to DMARD use.</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusions</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Levels of anti-TNFa drugs will change with DMARD treatment.</p></span>"
"secciones" => array:5 [
0 => array:2 [
"identificador" => "abst0005"
"titulo" => "Background and objectives"
]
1 => array:2 [
"identificador" => "abst0010"
"titulo" => "Objectives"
]
2 => array:2 [
"identificador" => "abst0015"
"titulo" => "Materials and methods"
]
3 => array:2 [
"identificador" => "abst0020"
"titulo" => "Results"
]
4 => array:2 [
"identificador" => "abst0025"
"titulo" => "Conclusions"
]
]
]
"es" => array:3 [
"titulo" => "Resumen"
"resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Antecedentes y objetivos</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">El conocimiento de los niveles de fármacos anti-TNFα puede modificar el tratamiento en pacientes con artritis reumatoide (AR) y espondiloartritis (EspA).</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Objetivos</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Comparar los niveles de anti-TNFα en pacientes con AR vs EspA, en diferentes situaciones clínicas.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Materiales y métodos</span><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Se realizó un estudio retrospectivo, observacional donde se midieron los niveles de anti-TNFα y la presencia de anticuerpos antifármacos en pacientes seleccionados consecutivamente, utilizando la técnica de ELISA.</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resultados</span><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Se estudiaron 53, 73 y 78 pacientes en tratamiento con infliximab, adalimumab y etanercept, respectivamente. Los niveles medios de fármaco en pacientes con dosis estándar fueron: infliximab 2,2 μg/mL (1,4–5,2), adalimumab 4,9 μg/mL (0,8−8,9) y etanercept 3,1 μg/mL (2,3–4,4). No se encontraron diferencias en los niveles fármacos según la actividad de la enfermedad, sin embargo, hubo diferencias en los niveles de etanercept e infliximab según el uso de fármacos modificadores de la enfermedad sintéticos (FAMEsc).</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Los niveles de fármacos anti-TNFα se verán modificados por el tratamiento con FAMEsc.</p></span>"
"secciones" => array:5 [
0 => array:2 [
"identificador" => "abst0030"
"titulo" => "Antecedentes y objetivos"
]
1 => array:2 [
"identificador" => "abst0035"
"titulo" => "Objetivos"
]
2 => array:2 [
"identificador" => "abst0040"
"titulo" => "Materiales y métodos"
]
3 => array:2 [
"identificador" => "abst0045"
"titulo" => "Resultados"
]
4 => array:2 [
"identificador" => "abst0050"
"titulo" => "Conclusiones"
]
]
]
]
"NotaPie" => array:1 [
0 => array:2 [
"etiqueta" => "☆"
"nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as: Meriño-Ibarra E, Manero Ruíz FJ. Niveles de fármacos anti-TNFα en pacientes con artritis reumatoide y espondiloartritis. Reumatol Clín. 2022;18:475–479.</p>"
]
]
"multimedia" => array:2 [
0 => array:8 [
"identificador" => "tbl0005"
"etiqueta" => "Table 1"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0005"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:3 [
"leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: Body Mass Index; CRP: C-reactive protein; DAS28: Disease Activity Score 28-joint counts; DMARDs: synthetic disease-modifying drugs.</p>"
"tablatextoimagen" => array:1 [
0 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col">Variable \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col">Rheumatoid arthritis \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col">Spondyloarthritis \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col">Total \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">N = 74 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">N = 119 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">N = 193 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Age (years)</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">59.8 (12.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">54.7 (14.0) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">56.7 (13.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.011 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Women, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">57 (77) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">44 (36.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">101 (52.3) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.000 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Infliximab (g/mL)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.10 (1.70−3.50) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.9 (0.85−6.50) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.3 (1.0−5.80) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.546 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Adalimumab (g/mL)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.80 (1.80−6.10) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5.40 (1.50−8.95) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.80 (1.80−8.60) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.272 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Etanercept (g/mL)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.60 (1.20−4.00) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.0 (.83−3.20) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.40 (1.0−3.45) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.200 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Biological therapy, N</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">74 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">119 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">193 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.022 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Infliximab<span class="elsevierStyleItalic">, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">16 (21.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">34 (28.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">50 (25.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Adalimumab<span class="elsevierStyleItalic">, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">19 (25.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">46 (38.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">65 (33.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Etanercept<span class="elsevierStyleItalic">, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">39 (52.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">39 (32.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">78 (40.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Time to disease progression, (years)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">12.6 (8.20−21.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">13.1 (6.64−22.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">12.9 (7.49−22.5) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.877 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Time on biologic therapy, (years)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5.87 (2.05−9.53) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.20 (1.80−9.14) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.85 (1.82−9.26) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.386 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">BMI, (kg/m<span class="elsevierStyleSup">2</span>)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">26.2 (22.6−29.1) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">25.8 (23.3−29.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">26.1 (23.1−29.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.325 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">CRP, (mg/dl)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.27 (.13−.70) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.24 (.11−.58) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.26 (.13−.61) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.555 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">DAS28, (CRP)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.79 (2.27−3.62) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">— \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2,79 (2,27−3,62) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">BASDAIa</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">— \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.47 (2.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.47 (2.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">ASDAS, (CRP)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">— \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1.70 (1.40−2.27) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1.70 (1.40−2.27) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">DMARDs, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">50 (67.5) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">27 (22.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">77 (39.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.000 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Methotrexate, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">33 (44.5) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">19 (15.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">52 (26.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leflunomide, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">16 (21.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5 (4.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">21 (10.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sulphasalazine, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1 (1.63) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3 (2.53) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4 (2.1) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Cases with suboptimal dose of anti-TNF, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">26 (35.1) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">39 (32.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">65 (33.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.735 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Infliximab, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5 (6.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">9 (7.56) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">14 (7.25) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Adalimumab, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5 (6.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">14 (11.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">19 (9.84) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Etanercept, N (%) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">16 (21.6) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">16 (13.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">32 (16.5) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Remission/low activity, N (%)</span> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">55 (74.3) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">88 (77.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">143 (76.5) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.575 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
]
"notaPie" => array:1 [
0 => array:3 [
"identificador" => "tblfn0005"
"etiqueta" => "a"
"nota" => "<p class="elsevierStyleNotepara" id="npar0005">Data expressed as mean (standard deviation), other continuous quantitative variables expressed as median (interquartile range).</p>"
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of variables assessed, by rheumatic disease.</p>"
]
]
1 => array:8 [
"identificador" => "tbl0010"
"etiqueta" => "Table 2"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0010"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:2 [
"leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">LDA: low disease activity; DMARDs: synthetic disease-modifying drugs.</p><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Results expressed as median (interquartile range).</p>"
"tablatextoimagen" => array:6 [
0 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleBold">A</span> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">anti-TNFα levels (μg/mL), N = 128 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.2 (1.4−5.25) \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.9 (.8−8.9) \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.1 (2.3−4.4) \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
1 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"><span class="elsevierStyleBold">B</span> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Remission/LDA vs. no remission/no LDA</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Rheumatoid arthritis N = 48</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Remission/LDA N = 33 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">No remission/no LDA N = 15 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.0 (1.5−2.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.4 (3.4−3.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.427 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">6.4 (2.8−8.0) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.0 (0.23−3.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.128 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.7 (2.3−4.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.0 (3.1−4.3) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.366 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
2 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Spondyloarthritis N = 80</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Remission/LDA N = 55 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">No remission/no LDA N = 25 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.4 (1.4−7.55) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.4(1.0−6.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.563 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">6.6 (0.45−9.95) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">7.2 (1.85−8.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.999 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.8 (2.4−3.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.2 (2.35−6.65) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.219 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
3 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleBold">C</span> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">DMARDs N = 52 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">No DMARDs N = 76 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.0 (2.2−6.0) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1.8 (1.0−2.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.035 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.2 (.7−8.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.9 (1.2−9.1) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.607 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.4 (2.6−4.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.5 (1.8−3.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.039 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
4 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"><span class="elsevierStyleBold">C1</span> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Rheumatoid arthritis N = 48</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">DMARDs N = 32 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">No DMARDs N = 16 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.2 (1.8−5.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.0 (1.55−2.75) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.520 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1.9 (0.7−7.45) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.9 (3.55−4.8) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.539 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.2 (2.6−4.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3.2 (1.95−4.9) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.833 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
5 => array:1 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Spondyloarthritis N = 80</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">DMARDs N = 20 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">No DMARDs N = 60 \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> value \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infliximab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5.4 (3.4−7.4) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.1 (0.95−6.65) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.223 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Adalimumab \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">9.3 (6.6−10.2) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">6.3 (0.55−9.7) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.607 \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Etanercept \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4.4 (3.3−6.1) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2.5 (1.95−3.25) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">.008 \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Anti-TNF drug levels in standard-dose patients. A: Overall results. B: Anti-TNF drug levels according to rheumatic disease and according to remission/low disease activity vs. no remission/no low disease activity. C: Drug levels according to treatment with DMARDs and C1 according to rheumatic disease.</p>"
]
]
]
"bibliografia" => array:2 [
"titulo" => "References"
"seccion" => array:1 [
0 => array:2 [
"identificador" => "bibs0005"
"bibliografiaReferencia" => array:15 [
0 => array:3 [
"identificador" => "bib0005"
"etiqueta" => "1"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "D.Y. Chen"
1 => "Y.M. Chen"
2 => "W.C. Tsai"
3 => "J.C. Tseng"
4 => "Y.H. Chen"
5 => "C.W. Hsieh"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/annrheumdis-2013-203893"
"Revista" => array:6 [
"tituloSerie" => "Ann Rheum Dis"
"fecha" => "2015"
"volumen" => "74"
"paginaInicial" => "1"
"paginaFinal" => "10"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/25477133"
"web" => "Medline"
]
]
]
]
]
]
]
]
1 => array:3 [
"identificador" => "bib0010"
"etiqueta" => "2"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "D. Pascual-Salcedo"
1 => "C. Plasencia"
2 => "S. Ramiro"
3 => "L. Nuño"
4 => "G. Bonilla"
5 => "D. Nagore"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1093/rheumatology/ker124"
"Revista" => array:5 [
"tituloSerie" => "Rheumatology (Oxford)"
"fecha" => "2011"
"volumen" => "50"
"paginaInicial" => "1445"
"paginaFinal" => "1452"
]
]
]
]
]
]
2 => array:3 [
"identificador" => "bib0015"
"etiqueta" => "3"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:5 [
0 => "I. Arstikyte"
1 => "G. Kapleryte"
2 => "I. Butrimiene"
3 => "A. Venalis"
4 => "G. Shi"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1155/2015/604872"
"Revista" => array:6 [
"tituloSerie" => "Biomed Res Int"
"fecha" => "2015"
"volumen" => "2015"
"paginaInicial" => "7"
"paginaFinal" => "9"
"itemHostRev" => array:3 [
"pii" => "S0022522319311134"
"estado" => "S300"
"issn" => "00225223"
]
]
]
]
]
]
]
3 => array:3 [
"identificador" => "bib0020"
"etiqueta" => "4"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "M. Terc"
1 => "M. Ogrič"
2 => "M. Terčelj"
3 => "S. Praprotnik"
4 => "M. Tomšič"
5 => "B. Božič"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1007/s12026-016-8824-8"
"Revista" => array:7 [
"tituloSerie" => "Immunol Res"
"fecha" => "2017"
"volumen" => "65"
"paginaInicial" => "172"
"paginaFinal" => "185"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/27421721"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0003497519301110"
"estado" => "S300"
"issn" => "00034975"
]
]
]
]
]
]
]
4 => array:3 [
"identificador" => "bib0025"
"etiqueta" => "5"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "J. Rosas"
1 => "María Martín-López"
2 => "T. Otón"
3 => "A. Balsa"
4 => "J. Calvo-Alén"
5 => "R. Sanmartí"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1016/j.reuma.2018.09.006"
"Revista" => array:6 [
"tituloSerie" => "Reumatol Clin"
"fecha" => "2020"
"volumen" => "16"
"paginaInicial" => "378"
"paginaFinal" => "385"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/30385295"
"web" => "Medline"
]
]
]
]
]
]
]
]
5 => array:3 [
"identificador" => "bib0030"
"etiqueta" => "6"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:3 [
0 => "A.A. den Broeder"
1 => "N. van Herwaarden"
2 => "B.J.F. van den Bemt"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1097/BOR.0000000000000487"
"Revista" => array:7 [
"tituloSerie" => "Curr Opin Rheumatol"
"fecha" => "2018"
"volumen" => "30"
"paginaInicial" => "266"
"paginaFinal" => "275"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/29389829"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0012369215346031"
"estado" => "S300"
"issn" => "00123692"
]
]
]
]
]
]
]
6 => array:3 [
"identificador" => "bib0035"
"etiqueta" => "7"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "T. Jurado"
1 => "C. Plasencia-Rodríguez"
2 => "A. Martínez-Feito"
3 => "V. Navarro-Compán"
4 => "T. Rispens"
5 => "A. Vries de"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.2174/1874312901711010075"
"Revista" => array:7 [
"tituloSerie" => "Open Rheumatol J"
"fecha" => "2017"
"volumen" => "11"
"paginaInicial" => "75"
"paginaFinal" => "87"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/28761564"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0022522319309687"
"estado" => "S300"
"issn" => "00225223"
]
]
]
]
]
]
]
7 => array:3 [
"identificador" => "bib0040"
"etiqueta" => "8"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Drug levels and antibodies against TNF-blockers in spondyloarthritis and rheumatoid arthritis are associated with the activity but they do not predict it"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:6 [
0 => "E.M. Padilla-Martínez"
1 => "C. Romero-Sánchez"
2 => "J.M. Bello-Gualtero"
3 => "A.M. Mesa-Betancourt"
4 => "W. Bautista Molano"
5 => "O.R. Valle"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.2174/1573397115666190708113601"
"Revista" => array:6 [
"tituloSerie" => "Curr Rheumatol Rev"
"fecha" => "2019"
"volumen" => "15"
"paginaInicial" => "329"
"paginaFinal" => "335"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/31284866"
"web" => "Medline"
]
]
]
]
]
]
]
]
8 => array:3 [
"identificador" => "bib0045"
"etiqueta" => "9"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "R. Sanmarti"
1 => "J. Inciarte-Mundo"
2 => "P. Estrada-Alarcon"
3 => "M. Garcia-Manrique"
4 => "J. Narvaez"
5 => "J. Rodriguez-Moreno"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/annrheumdis-2015-207530"
"Revista" => array:5 [
"tituloSerie" => "Ann Rheum Dis"
"fecha" => "2015"
"volumen" => "74"
"paginaInicial" => "e42"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/25805737"
"web" => "Medline"
]
]
]
]
]
]
]
]
9 => array:3 [
"identificador" => "bib0050"
"etiqueta" => "10"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Key findings towards optimising adalimumab treatment: the concentration-effect curve"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "M.F. Pouw"
1 => "C.L. Krieckaert"
2 => "M.T. Nurmohamed"
3 => "D. Van Der Kleij"
4 => "L. Aarden"
5 => "T. Rispens"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/annrheumdis-2013-204172"
"Revista" => array:7 [
"tituloSerie" => "Ann Rheum Dis"
"fecha" => "2015"
"volumen" => "74"
"paginaInicial" => "513"
"paginaFinal" => "518"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/24326008"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0169500207001833"
"estado" => "S300"
"issn" => "01695002"
]
]
]
]
]
]
]
10 => array:3 [
"identificador" => "bib0055"
"etiqueta" => "11"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "E.L. Kneepkens"
1 => "C.L.M. Krieckaert"
2 => "D. van Der Kleij"
3 => "M.T. Nurmohamed"
4 => "I.E. van Der Horst-Bruinsma"
5 => "T. Rispens"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/annrheumdis-2014-205213"
"Revista" => array:7 [
"tituloSerie" => "Ann Rheum Dis"
"fecha" => "2015"
"volumen" => "74"
"paginaInicial" => "1825"
"paginaFinal" => "1829"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/24812290"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0012369218326072"
"estado" => "S300"
"issn" => "00123692"
]
]
]
]
]
]
]
11 => array:3 [
"identificador" => "bib0060"
"etiqueta" => "12"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "The pharmacokinetics of biologics: a primer"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:1 [
0 => "D.R. Mould"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1159/000437077"
"Revista" => array:6 [
"tituloSerie" => "Dig Dis"
"fecha" => "2015"
"volumen" => "33 Suppl 1"
"paginaInicial" => "61"
"paginaFinal" => "69"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/26367860"
"web" => "Medline"
]
]
]
]
]
]
]
]
12 => array:3 [
"identificador" => "bib0065"
"etiqueta" => "13"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "E.H. Vogelzang"
1 => "M.F. Pouw"
2 => "M. Nurmohamed"
3 => "E.L. Kneepkens"
4 => "T. Rispens"
5 => "G.J. Wolbink"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/annrheumdis-2014-206588"
"Revista" => array:6 [
"tituloSerie" => "Ann Rheum Dis"
"fecha" => "2015"
"volumen" => "74"
"paginaInicial" => "474"
"paginaFinal" => "475"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/25433018"
"web" => "Medline"
]
]
]
]
]
]
]
]
13 => array:3 [
"identificador" => "bib0070"
"etiqueta" => "14"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "E. Ducourau"
1 => "T. Rispens"
2 => "M. Samain"
3 => "E. Dernis"
4 => "F. Le Guilchard"
5 => "L. Andras"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1136/rmdopen-2019-001047"
"Revista" => array:5 [
"tituloSerie" => "RMD Open"
"fecha" => "2020"
"volumen" => "6"
"paginaInicial" => "6"
"itemHostRev" => array:3 [
"pii" => "S1556086415309886"
"estado" => "S300"
"issn" => "15560864"
]
]
]
]
]
]
]
14 => array:3 [
"identificador" => "bib0075"
"etiqueta" => "15"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "S. Hässler"
1 => "D. Bachelet"
2 => "J. Duhaze"
3 => "N. Szely"
4 => "A. Gleizes"
5 => "S.H.B. Abina"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1371/journal.pmed.1003348"
"Revista" => array:4 [
"tituloSerie" => "PLoS Med"
"fecha" => "2020"
"volumen" => "17"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/32925970"
"web" => "Medline"
]
]
]
]
]
]
]
]
]
]
]
]
]
"idiomaDefecto" => "en"
"url" => "/21735743/0000001800000008/v1_202210070758/S217357432100215X/v1_202210070758/en/main.assets"
"Apartado" => array:4 [
"identificador" => "43294"
"tipo" => "SECCION"
"en" => array:2 [
"titulo" => "Original articles"
"idiomaDefecto" => true
]
"idiomaDefecto" => "en"
]
"PDF" => "https://static.elsevier.es/multimedia/21735743/0000001800000008/v1_202210070758/S217357432100215X/v1_202210070758/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432100215X?idApp=UINPBA00004M"
]